In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Improvement of endothelial function parameters during cardiac rehabilitation predicts recurrent chest pain in stable coronary artery disease patients-5 years follow up

Session Poster Session 3

Speaker Dejan Simonovic

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Cardiovascular Rehabilitation, Other
  • Session type : Poster Session

Authors : D Simonovic (Nis,RS), M Deljanin Ilic (Nis,RS), S Ilic (Nis,RS), G Kocic (Nis,RS), R Pavlovic (Nis,RS)

Authors:
D. Simonovic1 , M. Deljanin Ilic2 , S. Ilic3 , G. Kocic4 , R. Pavlovic4 , 1Institut Niska Banja - Nis - Serbia , 2Institute of Cardiology, Medical Faculty University of Nis, Niska Banja - Nis - Serbia , 3Internal Medicine Specialist Practice, “Cardiopiont” - Nis - Serbia , 4Institute of Biochemistry, Medical Faculty University of Nis - Nis - Serbia ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 500

Purpose: To evaluate the effects of cardiac rehabilitation on circulating blood markers of endothelial function: nitric oxide (NOx), Xanthine Oxidase (XO) and asymmetricdimethylarginine (ADMA), and their prognostic significance on recurrent chest pain.

Methods: 65 patients (pts) (58.82±4.25 years, all men) were admitted to cardiac rehabilitation after myocardial infarction (MI). All patients underwent a supervised 3 weeks exercise training. At baseline and after 3 weeks in all pts values of NOx, XO and ADMA were determined. Clinical long-term follow-up (5 years) was performed. All medical therapy were documented, and for this analysis, we focused on recurrent anginal chest pain.

Results: After follow-up period there were no cardiovascular (CV) hard end points (CV death, MI, stroke), however 35 pts (54%) had episodes of typical anginal chest pain (AP group) while 30 pts (46%) were without anginal chest pain (no-AP group). During rehabilitation NOx increased in both groups: in no-AP group (from 33.42±7.51 to 48.12±10.05 μmol/L, p<0.0001) and in AP group (from 34.55±6.22 to 41.10±5.15 μmol/L, p<0.001) with significantly higher second measurement in no-AP group (p=0.001). The mean NOx increase in no-AP group was higher than in AP group (14.70±8.85 vs 6.55±5.72, p<0.0001). XO levels decreased in both groups, with higher mean XO decrease in no-AP group (119.40±12.90 vs 89.30±12.85 μmol/L, p<0.001). Also, ADMA levels decreased in both groups, with higher mean ADMA decrease in no-AP group (0.07±0.05 vs 0.04±0.06 μmol/L, p=0.03). A positive correlation was found between NOx increase and XO decrease in all pts (r=0.922, p<0.001); also between NOx increase and ADMA decrease in all pts (r=0.834, p<0.001). Univaried logistic regression analyses were performed and showed that NOx increase (OR 0.792, CI 0.610 - 0.982, p<0.001), XO decrease (OR 0.812, CI 0.641–0.971, p=0.005) and ADMA decrease (OR 0.905, CI 0.829–0.974, p=0.002) significantly predict a 5 years period without anginal chest pain.

Conclusion: Residential cardiovascular rehabilitation, in patients with stable coronary artery disease, improved endothelial function. Patients with higher increase of NOx, and greater reduction in XO and ADMA values after 3 weeks of specialized cardiac rehabilitation, during 5 years follow up, were without anginal chest pain and without any CV event.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are